Abstract
There is a great unmet medical need in the area of cancer treatment. A potential therapeutic target for intervention in cancer is ADAM10. ADAM10 is a disintegrin-metalloproteinase that processes membrane bound proteins from the cell surface to yield soluble forms. Pharmaceutical companies are actively seeking out inhibitors of ADAM10 for treatments in cancer as the enzyme is known to release the ErbB receptor, HER2/ErbB2 from the cell membrane, an event that is necessary for HER2 positive tumor cells to proliferate. ADAM10 is also capable of processing betacellulin indicating that an inhibitor could be used against EGFR/ErbB1 and/or HER4/ErbB4 receptor positive tumor cells that are betacellulin- dependent. ADAM10 is the principle sheddase for several other molecules associated with cancer proliferation, differentiation, adhesion and migration such as Notch, E-cadherin, CD44 and L1 adhesion molecule indicating that targeting ADAM10 with specific inhibitors could be beneficial.
Keywords: CD44 shedding, Cell adhesion molecules, tumorigenesis, Notch signaling pathway, Epidermal growth factor
Current Pharmaceutical Biotechnology
Title: ADAM10 as a Target for Anti-Cancer Therapy
Volume: 9 Issue: 1
Author(s): Marcia L. Moss, Alexander Stoeck, Wenbo Yan and Peter J. Dempsey
Affiliation:
Keywords: CD44 shedding, Cell adhesion molecules, tumorigenesis, Notch signaling pathway, Epidermal growth factor
Abstract: There is a great unmet medical need in the area of cancer treatment. A potential therapeutic target for intervention in cancer is ADAM10. ADAM10 is a disintegrin-metalloproteinase that processes membrane bound proteins from the cell surface to yield soluble forms. Pharmaceutical companies are actively seeking out inhibitors of ADAM10 for treatments in cancer as the enzyme is known to release the ErbB receptor, HER2/ErbB2 from the cell membrane, an event that is necessary for HER2 positive tumor cells to proliferate. ADAM10 is also capable of processing betacellulin indicating that an inhibitor could be used against EGFR/ErbB1 and/or HER4/ErbB4 receptor positive tumor cells that are betacellulin- dependent. ADAM10 is the principle sheddase for several other molecules associated with cancer proliferation, differentiation, adhesion and migration such as Notch, E-cadherin, CD44 and L1 adhesion molecule indicating that targeting ADAM10 with specific inhibitors could be beneficial.
Export Options
About this article
Cite this article as:
Moss L. Marcia, Stoeck Alexander, Yan Wenbo and Dempsey J. Peter, ADAM10 as a Target for Anti-Cancer Therapy, Current Pharmaceutical Biotechnology 2008; 9 (1) . https://dx.doi.org/10.2174/138920108783497613
DOI https://dx.doi.org/10.2174/138920108783497613 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Validation of Human Clinical Genetic Tests
Mini-Reviews in Medicinal Chemistry Smac-Derived Aza-Peptide As an Aminopeptidase-Resistant XIAP BIR3 Antagonist
Protein & Peptide Letters Target Driven Preclinical Screening for New Antimitotic Chemotherapy Agents
Current Topics in Medicinal Chemistry Monoclonal Antibodies in the Management of Solid Tumors
Current Topics in Medicinal Chemistry Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy Molecular Remodeling of the Insulin Receptor Pathway by Thiazolidinediones in Type 2 Diabetes Mellitus: A Brief Review
Protein & Peptide Letters Breast Cancer and Flavonoids - A Role in Prevention
Current Pharmaceutical Design Antiproliferative and Proapoptotic Effects of the TrK-inhibitor GW441756 in Human Myosarcomas and Prostatic Carcinoma
Current Signal Transduction Therapy Targeting the EGFR-family for Therapy: Biological Challenges and Clinical Perspective
Current Pharmaceutical Design The Chemical Composition of Essential Oil of Warionea saharae Benth & Coss.(Fam.Asteraceae) from Southern Algeria
Current Bioactive Compounds Rationale Design, Synthesis, Cytotoxicity Evaluation, and Molecular Docking Studies of 1,3,4-oxadiazole Analogues
Anti-Cancer Agents in Medicinal Chemistry The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells
Current Molecular Medicine Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells
Current Cancer Therapy Reviews Antiproliferative Activity of 8-methoxy Ciprofloxacin-Hydrozone/Acylhydrazone Scaffolds
Current Topics in Medicinal Chemistry Spinophilin: A New Tumor Suppressor at 17q21
Current Molecular Medicine The PIK3CA Gene as a Mutated Target for Cancer Therapy
Current Cancer Drug Targets Nanotechnology Platforms; An Innovative Approach to Brain Tumor Therapy
Medicinal Chemistry Contrast Enhanced Ultrasonography for Focal Liver Lesions Characterization: Clinical Perspective
Current Medical Imaging Acridine Derivatives as Chemotherapeutic Agents
Current Medicinal Chemistry miRNA Functions in Arthritis
Current Rheumatology Reviews